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Among other functions, resident skin cells monitor their local environment for potential 
sources of threat and mount defenses against invasion by foreign micro-organisms. Most 
prominent in this innate defense system are keratinocytes, mast cells and dendritic cells (Metz 
and Maurer, 2009). Each of these cell types participate in cutaneous immune and allergic 
responses and, together, provide an integrated defense against infection and injury. Activation 
of epidermal keratinocytes by ultraviolet light or stimulation of toll-like receptors on their 
cell membrane evokes the release of antimicrobial peptides and secretion of pro-
inflammatory cytokines. Mast cells are acutely sensitive to their local environment and, when 
activated, secrete a wide array of biological mediators that play a pivotal role in the response 
to infection and tissue injury. Immune cells are drawn to the site of injury by chemical signals 
(chemokines) released by injured cells and by the actions of the innate defense system. 
Dermal and epidermal dendritic cells (Langerhans cells) then initiate immune responses by 
presenting antigens to cells of the adaptive immune system. 
These defensive processes are monitored and coordinated by sensory nerves. Noxious 
mechanical, chemical, thermal and electrical stimuli initiate axon-reflex vasodilatation (a 
flare) around the site of stimulation, thereby helping to disperse harmful substances and to 
recruit protective blood-borne cells and agents that quarantine and destroy invading microbes. 
This local response is triggered by the sensory afferents that detect noxious stimuli, and 
involves release of vasoactive neuropeptides from the axonal network around the site of 
stimulation. In humans, the axon-reflex flare is mediated primarily by calcitonin gene-related 
peptide (CGRP) with an additional contribution from substance P (Sauerstein et al., 2000). 
Besides their effect on vascular smooth muscle and endothelial cells, these neuropeptides 
communicate with resident skin cells. For example, stimulation of neurokinin-1 receptors by 
substance P induces proliferation of keratinocytes, release of cytokines from mast cells and 
functional activation of dendritic cells (Peters et al., 2006), responses that are important for 
wound healing and protection against infection. Conversely, pro- and anti-inflammatory 
mediators released from resident skin and infiltrating immune cells influence the excitability 
of cutaneous sensory neurons. The two-way communication between these cells and sensory 
nerves helps to fine-tune local inflammatory responses while also informing the central 
nervous system about developments that might require systemic intervention. 
 
One of the key regulators of inflammation is tumor necrosis factor-α (TNF-α) (Bradley, 
2008). Although activated macrophages and T lymphocytes provide the main source of TNF-
α in the skin, a wide range of resident skin cells can also produce this cytokine (Metz and 
Maurer, 2009). TNF-α is a modulator of the host response to infection and of programmed 
cell death, and acts upon the vascular endothelium to increase adhesion and transendothelial 
migration of leukocytes to sites of inflammation (Bradley, 2008). TNF-α also generates a 
cytokine cascade that can sensitize cutaneous sensory afferents via at least two pathways. The 
first involves cyclo-oxygenase with production of hyperalgesic prostaglandins, whereas the 
second involves chemokines and the subsequent release of sympathetic amines (Cunha et al., 
1992 and Cunha et al., 2008). As noted below, the second pathway could implicate the 
sympathetic nervous system in neuro-inflammatory pain syndromes. 
 
Given these properties, it is not surprising that TNF-α plays an important role in various 
chronic inflammatory diseases, including rheumatoid arthritis, neuropathic pain, 
inflammatory bowel disease and psoriasis (Bradley, 2008). TNF-α is elevated in the affected 
tissue of patients with complex regional pain syndrome (CRPS) (Huygen et al., 
2002 and Bernateck et al., 2010), a chronic pain condition that generally starts after 
peripheral nerve or tissue injury (Drummond, 2001 and Gibbs et al., 2008). The 
consequences of this elevation were explored recently in an animal model of CRPS involving 
distal tibia fracture (Sabsovich et al., 2008). TNF-α was found to be over-expressed in 
affected skin and sciatic nerve four weeks after the fracture. This was associated with 
behavioural signs of pain and spinal Fos activation, a marker of nociceptive signaling. These 
responses were blocked by pre-emptive treatment with a TNF-α antagonist, suggesting that 
TNF-α is an important mediator of pain following tibial fracture. Further characterization of 
the pain model indicated that substance P signaling through enhanced neurokinin-1 receptor 
expression in keratinocytes activated pro-inflammatory cytokines (Wei et al., 2009). This 
raises the possibility that release of substance P from nociceptive neurons evokes a cytokine 
cascade from resident skin cells that ultimately results in sensitization of the nociceptors that 
began the process. If left unchecked, this vicious circle could result in chronic inflammation 
and pain. 
It is becoming increasingly clear that pro-inflammatory processes involving keratinocytes are 
fundamental in certain forms of neuropathic pain. To illustrate this point, Radtke et al. (2010) 
transplanted human keratinocytes at the site of a severed sciatic nerve in a rat model of 
neuropathic pain. The keratinocytes assembled into a cellular structure that resembled the 
stratum spinosum of the epidermis. Levels of the prototypic neurotrophin, nerve growth 
factor (NGF), rose substantially at the transplant site. In addition, the cell bodies of primary 
afferent neurons whose cut axons were present near the transplanted keratinocytes became 
highly excitable and animals displayed behavioural signs of pain (autotomy of the nerve-
injured limb). These effects were greater than those induced by ligation alone; moreover, 
keratinocytes injected into an intact sciatic nerve neither assembled into a cellular structure 
nor induced behavioural or electrophysiological signs of pain. NGF is crucial for the survival 
of sensory and sympathetic neurons, and also regulates axonal growth, synaptic plasticity, the 
expression of ion channels and neurotransmission via tyrosine kinase A receptors (Reichardt, 
2006). Some of these effects may be driven by TNF-α during inflammation, as TNF-α 
enhances the synthesis of NGF from cultured human keratinocytes (Takaoka et al., 2009). 
Together, the findings presented by Radtke et al. show that the context in which sensory 
afferents and resident skin cells interact is critically important—and shifts dramatically after 
nerve injury. 
 
In a study published recently in Experimental Neurology, Eberle et al. (2010) measured 
intradermal TNF-α of healthy volunteers in response to two forms of sensory stimulation. 
The first involved shooting small plastic cylinders (0.5 g at 11 m/s) 120 times each at three 
adjacent skin sites in the forearm over a 30-min period. This produced a mildly painful 
sensation by the end of stimulation (rated 0.9 on a 0–10 pain rating scale) but no tenderness 
in the surrounding skin. The second form of stimulation involved intradermal electrical 
impulses (1 Hz, 0.5 ms duration, increasing to 20 mA within the first 5 min of a 30-min 
period of stimulation). This produced a moderately painful sensation by the end of 
stimulation (rated 6.3 on the pain scale) and half of the participants reported tenderness in 
surrounding skin, reflecting sensitization of central nociceptive neurons. Laser Doppler 
imaging indicated that electrical stimulation produced a flare that persisted for at least 
90 min, whereas impact stimuli produced a flare during the first 10 min that subsided 
thereafter. Surprisingly, there was no apparent association between the neuropeptide-
mediated flare and intradermal TNF-α, as TNF-α increased approximately 5-fold during the 
hour following impact stimuli but remained unchanged both during and after painful 
electrical stimulation. 
 
These findings are interesting for at least two reasons. First, they illustrate that activity in 
cutaneous nociceptors (which generates pain, tenderness and flares) does not necessarily 
result in release of TNF-α. In vitro, substance P and CGRP trigger the release of TNF-α and 
other cytokines in a concentration-dependent manner from fibroblasts prepared from human 
dental pulp tissue (Yamaguchi et al., 2004), and increase mRNA for a range of cytokines 
including TNF-α in cultured human keratinocytes (Dallos et al., 2006). Thus, the machinery 
exists for cells (including human skin cells) to manufacture cytokines in response to 
stimulation by neuropeptides. However, outcomes may be more complex in vivo as CGRP 
impedes immune cell activity (Gomes et al., 2005) and inhibits production of TNF-α in 
Langerhans cells following exposure to lipopolysaccharide (Ding et al., 2007). Thus, the net 
result following nociceptor activation might depend on the relative concentrations of pro-
inflammatory neuropeptides, such as substance P, and anti-inflammatory neuropeptides like 
CGRP. In human skin, a predominance of CGRP secreted from the peripheral terminals of 
nociceptive neurons during axon-reflex flares (Sauerstein et al., 2000) may explain why TNF-
α did not increase following intradermal electrical stimulation in the study by Eberle et al. 
(2010). It would be interesting to determine whether electrical stimulation is more effective in 
inflammatory and neuropathic pain syndromes characterized by heightened TNF-α signaling, 
because confirmation of a vicious circle between substance P and cytokine release could lead 
to insights about the pathogenesis of these syndromes. 
 
The second intriguing observation by Eberle et al. (2010) was the increase in levels of TNF-α 
in the dermal interstitial fluid 1 h after the train of impact stimuli. Inflammatory responses 
generally evolve over a period of hours or days rather than minutes because it takes time to 
manufacture cytokines. For instance, exposure to ultraviolet B light induces a biphasic 
increase in pro- and anti-inflammatory cytokines with an initial peak at 3–6 h and a second 
peak at 48 h (Saade et al., 2008). Curiously, both peaks depend to some extent upon the 
viability of capsaicin-sensitive cutaneous nociceptors and sympathetic efferents. Specifically, 
sympathetic efferents are required for TNF-α production both after ultraviolet B stimulation 
(Saade et al., 2008) and after intraplantar injection of bacterial endotoxin (Safieh-Garabedian 
et al., 2002); this inflammatory link might account, at least in part, for involvement of the 
sympathetic nervous system in CRPS (Gibbs et al., 2008). To explain the time course of 
TNF-α release after mechanical stimulation, Eberle et al. postulated that impact stimuli 
dislodged preformed stores of TNF-α into the interstitial fluid, possibly from mast cells 
(Gibbs et al., 2001). Alternatively, rapid de novo synthesis might account for the 90-min 
delay between stimulus onset and detection of TNF-α in the dermal interstitial fluid. 
 
At present, the relevance of these findings for neuropathic pain remains unclear. Both in 
terms of neural discharge and pain behaviour, sensitivity to TNF-α increased in uninjured 
primary afferent neurons after spinal nerve ligation (an animal model of neuropathic pain that 
resembles CRPS), possibly due to the products of infiltrating immune cells or release of 
neurotrophins such as NGF (Schafers et al., 2003). Moreover, preemptive treatment with a 
TNF-α antagonist inhibited allodynia both in this model (Schafers et al., 2003) and after 
distal tibia fracture (Sabsovich et al., 2008), pointing to the importance of TNF-α in the 
genesis of neuro-inflammatory pain. Whether preformed stores of TNF-α contribute 
significantly to this process requires further investigation. 
 
Benefits of TNF-α treatment for CRPS have been identified in uncontrolled case studies 
(Huygen et al., 2004 and Bernateck et al., 2007) but await confirmation in randomized 
controlled trials. In the meantime, the findings of Eberle et al. (2010) indicate that innocuous 
mechanical stimulation of healthy skin is sufficient to raise intradermal levels of TNF-α, 
independent of activity in cutaneous nociceptive neurons. Cutaneous nerves might be more 
influential in the context of inflammation or nerve injury, due to sensitization of primary 
nociceptive afferents and up-regulation of TNF-α and other inflammatory mediators 
produced by resident skin cells (Sommer and Kress, 2004 and Sabsovich et al., 2008). In any 
event, the findings of Eberle et al. (2010) suggest that even minor mechanical stimulation of 
affected regions may be sufficient to maintain inflammation and pain in patients with chronic 
neuro-inflammatory disease. If so, blocking the inflammatory response ought to be given 
priority over physical treatments that might inadvertently aggravate symptoms and cause the 
syndrome to persist. 
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